Transcriptomic Inference of Cancer Drug Sensitivity

This direction is split into other directions: pharmacogenomic sensitivity mapping, transcriptomic drug sensitivity prediction. Its last version stays readable and citable here.

Version 1 of 1134 papers157 conceptsfrozen 2026-10-04

In traditional oncology, drug selection often relies on broad clinical categories or single genetic mutations. However, tumors with the same diagnosis frequently respond differently to the same treatment. A growing body of research proposes a shift in perspective: treating the tumor's entire gene expression profile—its transcriptome—as a high-dimensional map of its therapeutic vulnerabilities.

By using computational models to link these transcriptomic "signatures" to large-scale drug response databases, researchers can now predict the efficacy of thousands of compounds for individual patients before they ever receive a dose.

Drugs as Biological Classifiers

To understand why this works, we can re-imagine the relationship between a drug and a cell. As Patrick N. Lawlor, Konrad Kording, and colleagues argue in Conceptualizing Cancer Drugs as Classifiers, a drug is essentially a mathematical classifier. It "senses" the molecular markers within a cell and, based on that input, "decides" whether to trigger a binary outcome: life or death.

Because individual drugs often act as "weak learners"—imperfect classifiers that only respond to a subset of molecular signals—the goal of precision medicine is to identify which specific cellular profiles a drug is "trained" to kill. By formalizing drug action as a computation, we can move from trial-and-error to a systematic selection of agents that maximize lethality for a specific tumor profile while sparing healthy tissue.

Bridging the Gap with Pharmacogenomics

The core mechanism of this research direction involves bridging two distinct datasets:

  1. Patient Transcriptomics: Bulk or single-cell RNA sequencing that captures the expression levels of thousands of genes in a patient's tumor.
  2. Pharmacogenomic Databases: Large-scale repositories (such as GDSC or CTRP) that record how thousands of cancer cell lines respond to various drugs, usually measured by the half-maximal inhibitory concentration (IC50).

The challenge is that patient tumors are not identical to lab-grown cell lines. To solve this, researchers like Yu Xiao and Junxin Wu use statistical techniques like ridge regression to train models on cell line data and then project those models onto patient data (Characterization of positively regulate T cell proliferation-related genes in hepatocellular cancer to guide clinical therapy). This allows for the in silico estimation of drug sensitivity, identifying which patients might be "high-risk" but paradoxically more sensitive to specific chemotherapies.

From Individual Genes to Biological Pathways

While early models focused on individual "hub" genes, recent work has shifted toward higher-level biological processes. Instead of looking at one gene, researchers develop "risk scores" based on conserved pathways like ferroptosis (The ferroptosis signature predicts the prognosis and immune microenvironment of nasopharyngeal carcinoma), lysosomal function (Hairong Su et al., Establishment of a lysosome-related prognostic signature in breast cancer), or polyamine metabolism (Zhouhua Li et al., Characterization of polyamine metabolism predicts prognosis).

This pathway-centric approach is more robust because it captures the "state" of the cell rather than the noise of a single gene. As Smriti Chawla and colleagues demonstrate, deep learning frameworks that prioritize pathway activity can generalize across cell lines, animal models, and human clinical data, effectively tracking how resistance emerges over time (Gene expression based inference of drug resistance in cancer).

The Logic of Transcriptomic Reversal

One of the most intuitive frameworks in this field is the Reverse Gene Expression Score (RGES). In Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets, Bin Chen posits that an effective drug is one that "flips" the cancer's transcriptomic profile back toward a healthy state.

If a cancer signature shows 100 genes are overexpressed, the ideal drug is the one that most strongly suppresses those specific 100 genes. By quantifying this "reversal," researchers can screen thousands of existing, FDA-approved drugs to find new uses for them—a process known as drug repurposing. For example, this method has identified that the anti-parasitic drug pyrvinium pamoate may be effective against certain cancers by reversing their specific genetic signatures.

Stratifying the Immune Landscape

Finally, transcriptomic inference is being used to navigate the complex world of immunotherapy. By calculating scores like the Tumor Immune Dysfunction and Exclusion (TIDE) score, researchers can predict which tumors are "hot" (likely to respond to checkpoint inhibitors) versus "cold" (likely to resist them).

As shown by Liang Sun in Disulfidptosis signature predicts immune microenvironment and prognosis of gastric cancer, these signatures can distinguish between patients who need immune-stimulating therapies and those who are better candidates for traditional chemotherapy. This multi-layered stratification—combining metabolic, immune, and drug-sensitivity signatures—represents the current frontier of personalized oncology.

Papers in this version

Showing 60 of 134 papers.

History & citationVersion 1 · 2026-10-04

Split into other directions · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_transcriptomic_inference_of_cancer_drug__7a9bc9f2,
  title = {Transcriptomic Inference of Cancer Drug Sensitivity},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/transcriptomic-inference-of-cancer-drug-sensitivity/rdr_7a9bc9f2d4b84604ba048589955a406a},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}

This exact version (version 1, frozen text):

@misc{lacuna_transcriptomic_inference_of_cancer_drug__7a9bc9f2_v1,
  title = {Transcriptomic Inference of Cancer Drug Sensitivity},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/transcriptomic-inference-of-cancer-drug-sensitivity/rdr_7a9bc9f2d4b84604ba048589955a406a/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}